O
UTHR icon

Ossiam’s United Therapeutics UTHR Stock Holding History

Ossiam’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$268K Sell
494
-128
-21% -$72.1K ﹤0.01% 562
2026
Q1 		$369K Buy
622
+62
+11% +$30.9K 0.01% 307
2025
Q4 		$273K Sell
560
-372
-40% -$173K 0.01% 319
2025
Q3 		$391K Sell
932
-92
-9% -$30.9K 0.01% 568
2025
Q2 		$294K Sell
1,024
-432
-30% -$129K ﹤0.01% 518
2025
Q1 		$449K Sell
1,456
-267
-15% -$91.5K 0.01% 432
2024
Q4 		$608K Sell
1,723
-330
-16% -$121K 0.01% 431
2024
Q3 		$736K Sell
2,053
-141
-6% -$47.6K 0.01% 398
2024
Q2 		$699K Buy
2,194
+50
+2% +$13.2K 0.01% 409
2024
Q1 		$493K Sell
2,144
-3,081
-59% -$695K 0.01% 494
2023
Q4 		$1.15M Sell
5,225
-1,544
-23% -$356K 0.02% 338
2023
Q3 		$1.53M Buy
6,769
+5,567
+463% +$1.28M 0.03% 259
2023
Q2 		$265K Buy
1,202
+726
+153% +$161K ﹤0.01% 555
2023
Q1 		$107K Buy
476
+13
+3% +$3.21K ﹤0.01% 595
2022
Q4 		$129K Hold
463
– – ﹤0.01% 535
2022
Q3 		$97K Buy
+463
New +$104K ﹤0.01% 575

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Ossiam's UTHR Position: Q2 2026 in Review

Ossiam reduced its United Therapeutics (UTHR) stake by 21% in Q2 2026, selling an estimated $72.1K and leaving 494 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #562.

Ossiam first reported a position in UTHR in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.53M in Q3 2023. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Ossiam held 494 shares of United Therapeutics worth $268K as of Q2 2026.
  • Ossiam sold 128 United Therapeutics shares in Q2 2026, an estimated $72.1K.
  • United Therapeutics made up ﹤0.01% of Ossiam's portfolio in Q2 2026, its #562 holding.
  • Ossiam first reported a position in United Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Ossiam's United Therapeutics position peaked at $1.53M in Q3 2023.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Ossiam's 13F filing for Q2 2026, filed 13 Aug 2026.